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ABSTRACT
Purpose: Mammalian target of rapamycin (mTOR) is a promising therapeutic 
target in advanced lung carcinoid patients. However, the mechanisms of mTOR 
modulation and of responsiveness to mTOR inhibitors are largely unclear. Our aim 
was to analyze the expression and functional role of specific miRNAs in lung carcinoids 
as an alternative mechanism targeting mTOR pathway.
Experimental design: Seven miRNAs, selected by bioinformatic tools and 
literature search, were analyzed in 142 lung neuroendocrine neoplasms (92 carcinoids 
and a control group of 50 high grade neuroendocrine carcinomas), and compared 
with mTOR mRNA expression and clinical/pathological parameters. Tissue results 
were validated in vitro in two lung carcinoid cell lines by specific RNA interference 
and biological/pharmacological tests.
Results: Tissutal expression of five miRNAs (miR-99b, miR-100, miR-155, miR-
193a-3p, miR-193a-5p) was inversely correlated with mTOR mRNA expression, 
supporting their role in the negative regulation of mTOR transcription. High expression 
of miR-100, miR-193a-3p and miR-193a-5p was associated with aggressive features 
and, for the former two, with shorter time to progression. In H727 and UMC11 lung 
carcinoid cells, miR-100 modulated mTOR RNA and TORC1 complex protein expression, 
positively promoted cell migration and negatively influenced cell proliferation. 
Moreover, miR-100 directly influenced responsiveness of H727 and UMC11 cells to 
rapamycin.
Conclusions: MiR-100 actively participates to the regulation of mTOR expression 
in lung carcinoids and represents a novel candidate prognostic biomarker for 
this tumor type; moreover, inhibition of its expression is associated to increased 
responsiveness to mTOR inhibitors and might represent a novel strategy to sensitize 
lung carcinoids to these target agents.
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INTRODUCTION
The mammalian target of rapamycin (mTOR) is a 
downstream effector of PI3K/AKT kinases and acts through 
two complexes, mTORC1 and mTORC2. MTORC1 
promotes cell growth, cell cycle progression and anabolism, 
such as protein and lipid biogenesis, and at the same time 
inhibits catabolism by blocking authophagy; conversely, 
mTORC2 regulates cell survival, cell proliferation and 
metabolism [1]. 
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Rapamycin and its derivatives, such as everolimus, 
are selective mTOR inhibitors that have been shown 
to block mTOR modulation of cell cycle progression, 
angiogenesis and apoptosis in several tumor cell models 
[2]. Few studies in lung carcinoid cells demonstrated a 
significant efficacy of mTOR inhibition strategies [3, 4], 
and supported the current indications for mTOR inhibitors 
present in the most recent clinical guidelines [5, 6]; 
moreover, a recent prospective clinical trial indicates 
a significant improvement of survival in patients with 
progressive lung neuroendocrine tumors treated with 
everolimus [7]. 
The clinical efficacy of mTOR inhibitors in lung 
carcinoids – and neuroendocrine cancer in general - might 
be improved by identifying i) the molecular mechanisms 
of mTOR pathway activation in cancer cells, and - as a 
consequence – ii) predictive markers of response to mTOR 
inhibitors. Indeed, while high levels of mTOR activation 
have been described in lung carcinoids in “prevalence” 
studies [8], no data are available about the correlation 
between specific activation profiles and response to 
therapy. Data obtained from primary tumor cell cultures, 
only, claim that patients with high levels of mTOR 
activation are associated with better responses [9]. 
Concerning the mechanisms leading to mTOR 
pathway deregulation, molecular alterations in oncogenes 
and tumor suppressor genes that are members of the 
pathway were recently found in lung neuroendocrine 
neoplasms, but with a relatively low prevalence in 
carcinoids [10, 11]. Thus, it has to be hypothesized 
that alternative regulators are responsible for mTOR 
expression. Among others, miRNAs are involved in 
regulating the mTOR pathway in several ways, either 
by targeting key genes within the pathway or interacting 
directly with mTOR. Several microRNAs (miRNAs) have 
been reported to selectively modulate mTOR pathway in 
other tumor models [12], but never in lung carcinoids. 
MiR-100, miR-199a-3p and miR-99 (a and b) directly 
target the 3ʹ-UTR of mTOR and suppress translation 
of its mRNA, and were found to be deregulated in 
hepatocellular, ovarian and prostate cancers, osteosarcoma, 
and adrenocortical tumors [13–16]. MiRNAs 193a-3p and 
-5p have been shown to down-regulate mTOR pathway 
in non-small cell lung cancer [17]. Moreover, several 
studies investigated the efficacy of combining mTOR 
inhibitors with mimic miRNAs in cancer cell models, 
and microRNA-driven mTOR modulation might have 
therapeutic benefit increasing sensitivity not only to 
rapamicin analogs but also to different anticancer drugs 
such as doxorubicin, cisplatin and taxanes [15, 18, 19].
Based on the above findings, the aim of this study 
was to analyze in primary lung carcinoids and cell models 
the expression and the functional role of selected miRNAs 
targeting mTOR, as an alternative mechanism of mTOR 
pathway regulation. 
RESULTS
mTOR gene and mTOR-targeting miRNAs 
expression levels are inversely correlated in 
tissue samples of lung neuroendocrine neoplasm, 
and associated with tumor histotype
The reciprocal expression of the markers investigated 
was checked (Table 1) and a significant negative correlation 
between all but two (miR-99a and miR-199) miRNAs 
and mTOR gene expression was observed, indicating a 
potential role in controlling mTOR transcription. Moreover, 
the expression of all miRNAs was positively correlated 
each other, although with a variable degree of statistical 
significance and pattern of association. However, TORC1 
complex-associated phosphorylated forms of mTOR 
and p70S6K, although strongly associated each other 
(Spearman’s R 0.28, p < 0.001) were not significantly 
associated with any of the miRNAs (all p values > 0.05). 
The expression levels of mTOR gene and mTOR-
targeting miRNAs were clearly different between 
the histologic subtype of pulmonary neuroendocrine 
neoplasms. In pairwise comparison, the expression 
levels of mTOR and miRNAs were significantly higher 
in carcinoid tumors than in high-grade neuroendocrine 
carcinoma (LCNECs and SCCs, used as control groups), 
except for miR-155 and miR-199 that were expressed at 
higher levels in high-grade neuroendocrine carcinomas 
(all p < 0.01). Moreover, miR-100, miR-193a-3p and miR-
193a-5p were down regulated in TC as compared to AC 
(p < 0.0001, p = 0.001 and p = 0.001, respectively); by 
contrast, miR-99a and mTOR were higher in TC than AC 
(p = 0.01 and p < 0.0001, respectively). 
High expression of miR-100, miR193a-5p and 
miR193a-3p is associated with aggressive disease 
in lung carcinoids
The association of mTOR-targeting miRNAs 
expression with specific tumor characteristics was assessed 
in the subgroup of carcinoids, only. High-grade carcinomas, 
that are characterized by a completely different clinical and 
biological behavior, were excluded from this analysis.
Over-expression of miR-100 correlated with tumor 
characteristics associated to a more aggressive phenotype. 
Indeed, (Supplementary Figure 1) miR-100 expression 
level was increased in patients with lymph node metastasis 
(p = 0.04), higher tumor stage (p = 0.004), worse disease 
status (p = 0.04), higher tumor grade (p = 0.0004), and 
presence of vascular invasion (p = 0.02; not shown). 
Similar results were obtained for both miR-193a-3p and 
miR-193a-5p that were expressed at higher levels in G2 
vs G1 tumors (p = 0.006 and p = 0.01, respectively) and in 
patients with worse disease status (p = 0.03 and p = 0.01, 
respectively).
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High expression of miR-100 and miR-193a-3p 
is associated with unfavorable prognosis in lung 
carcinoids
Time to progression (TTP) in patients with low 
miR-100 levels was significantly longer than in patients 
with higher levels (142 versus 101 months, log-rank 6.0, 
p = 0.01; Figure 1). Similar results were obtained for 
miR-193a-3p (undefined versus 101 months, log-rank 
4.4, p = 0.04). However, both miR-100 and miR-193a-3p 
failed to show any statistical significance in the specific 
group of atypical carcinoids, only (p = 0.24 and p = 0.48, 
respectively). Among clinical and pathological parameters, 
sex, tumor histotype, tumor grade and vascular invasion 
were also associated with TTP (Table 2). At multivariable 
Cox regression analysis, sex, histotype and grade were 
identified as independent poor prognostic variables.
mTOR is targeted by miR-100 in lung carcinoid 
cells 
In vitro experiments were designed to test the specific 
modulation of mTOR expression by the three miRNAs 
showing the most significant statistical correlation in tissue 
samples: miR-100, miR-193a-3p and miR-193a-5p. MiR-
100 was inversely associated with mTOR expression, with 
higher levels in low-mTOR expressing UMC-11 cells 
and lower levels in high-mTOR expressing H727 cells 
(Figure 2A). Dual-luciferase reporter assay showed that 
co-transfection of miR-100 significantly suppressed the 
activity of firefly luciferase reporter by binding the wild-
type 3ʹUTR of mTOR, whereas this effect was abrogated 
when the HEK-293T cells were co-transfected using 
scrambled negative control (Figure 2B). MiR-193a-3p 
and -5p levels were not associated with mTOR expression 
Table 1: Reciprocal correlation among mTOR mRNA and miRNAs expression levels
mTOR miR99a mir99b miR100 miR199 miR155 miR193a-3p 
miR99a r = 0.09p = 0.2 
mir99b r = –0.2p = 0.02 
r = –0.1
p = 0.3 
miR100 r = –0.4p < 0.0001 
r = 0.2
p = 0.03 
r = 0.2
p = 0.02 
miR199 r = –0.1p = 0.2 
r = 0.2
p = 0.1 
r = 0.07
p = 0.5 
r = 0.08
p = 0.4 
miR155 r = –0.3p = 0.01 
r = –0.1
p = 0.2 
r = 0.2
p = 0.03 
r = 0.3
p = 0.003 
r = 0.5
p < 0.0001 
miR193a-3p r = –0.4p = 0.0004 
r = 0.2
p = 0.04 
r = 0.2
p = 0.01 
r = 0.2
p = 0.03 
r = 0.3
p = 0.009 
r = 0.3
p = 0.003 
miR193a-5p r = –0.5p < 0.0001 
r = –0.1
p = 0.2 
r = 0.1
p = 0.08 
r = 0.2
p = 0.01 
r = 0.4
p < 0.0001 
r = 0.6
p < 0.0001 
r = 0.5
p < 0.0001 
Figure 1: TTP analysis in lung carcinoid patients. Kaplan Meier curves of survival in terms of time to progression in lung carcinoid 
patients segregated according to miR-100 (142 versus 101 months, log-rank 6.0, p = 0.01) and miR-193a-3p (undefined versus 101 months, 
log-rank 4.4, p = 0.04) expression levels.
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neither in H727 nor in UMC-11 cells (data not shown), 
and luciferase activity was unaffected by miR-193a-3p 
or weakly suppressed by miR-193a-5p (data not shown). 
Therefore, miR-193a-3p and miR-193a-5p were not further 
considered for functional analyses. The restoration of miR-
100 by means of miR-100-mimic transfection reduced the 
expression of mTOR at both mRNA (Figure 2C–2F) and 
protein (Figure 2G, 2H and Supplemental Figure 2) level 
in H727 and UMC11 cells, whereas the transfection of the 
antagonist of endogenous miR-100 (mir-100-inhibitor) 
increased the levels of mTOR protein and mRNA in both 
cells. Moreover, the same trend observed for mTOR protein 
in the different models in both cell lines was observed for 
the phosphorylated forms of mTOR and p70S6K, that are 
associated with TORC1 complex activation [20], whereas 
TORC2 was unaltered by miR100 up- or down-modulation, 
as demonstrated by the absence of significant changes in the 
phosphorylation status of AKT in S473 and of NDRG1 in 
T346, both known to be phosphorylated as a consequence 
of TORC2 activation [21]. 
MiR-100 inhibition sensitizes lung carcinoid cells 
to rapamycin treatment
To verify the hypothesis that miR-100 is functionally 
involved in lung carcinoid sensitivity to rapamycin, we 
tested H727 and UMC-11 cells in viability assays at basal 
conditions (transfection with mimic and inhibitor control) 
and after miR-100 modulation (transfection with miR-100 
mimic or inhibitor). The IC50 value of rapamycin was higher 
in UMC-11 wild type (wt) cells that express miR-100 at 
higher levels than in H727 wt cells (1.1 µM vs 0.6 µM; 
p < 0.0001). Up-modulation of miR-100 in H727-mimic-
miR-100 and UMC-11-mimic-miR-100 significantly 
reduced the effect of rapamycin (IC50 = 1.3 µM 
and IC50 = 1.5 µM, respectively) (Figure 3A and 3C) 
as compared with cells transfected with mimic negative 
control (IC50 = 0.57 µM and IC50 = 0.92 µM respectively; 
p < 0.05). In addition, down-regulation of miR-100 in H727 
and UMC-11 cells transfected with inhibitor-miR-100 
enhanced the effect of rapamycin at high concentrations 
(IC50 = 0.59 µM vs IC50 = 0.9 µM 1 and IC50 = 0.97 µM 
vs IC50 = 1,47 µM respectively p < 0.05) (Figure 3B 
and 3D). To further analyze the effects of miR-100 in the 
modulation of rapamycin-induced mTOR inhibition, we 
examined apoptosis in H727 cells with and without miR-
100 overexpression. Apoptosis was enhanced in H727-
inhibitor miR-100 cells as compared to controls (10% vs 
2% at 1 µM; p < 0001; 15.9% vs 8.2% at 10 µM, p = 001) 
and was strongly abolished in H727-mimic miR-100 cells 
as compared to controls (p = 0004 at 1 µM and p < 0001 at 
10 µM) (Figure 3E and 3F).
MiR-100 modulates proliferation and migration 
of lung carcinoid cells 
To investigate additional functional mechanisms 
of miR-100 in lung carcinoid cells, we evaluated the 
role of miR-100 in the control of H727 proliferation 
and migration. Over-expression of miR-100 markedly 
Table 2: Univariate and multivariate survival analyses of time to progression in 69 lung carcinoid patients
Parameter
Univariate Multivariate (Cox regression) 
HR (CI) p HR (CI) p 
Sex (M vs F) 4.877 (1.6–14.6) 0.0046 0.008 (0.0–0.2) 0.003 
Age (above vs below median) 1.537 (0. 5–4.8) 0.4633 / / 
Histotype (AC vs TC) 6.911 (2.2–21.9) 0.001 126.804 (5.5–2905.7) 0.002 
Rindi’s Grade (2 vs 1) 8.399 (2.3–31.0) 0.0014 0.115 (0.01–1.02) 0.048 
Size (above vs below mean) 1.635 (0.5–5.5) 0.4263 / / 
Clinical stage 
(all others vs IA/B) 1.020 (0.3–3.4) 0.974 / / 
Nodal status (N+ vs N0) 1.059 (0.3–3.4) 0.932 / / 
Vascular invasion (VI+ vs VI–) 7.535 (1.7–32.7) 0.007 3.405 (0.9– 12.9) 0.07 
Ki-67 (≥4 vs <4) 2.479 (0.8–8.1) 0.1314 / / 
Ki-67 (above vs below mean) 2.686 (0.8–9.4) 0.1207 
miR-100 (above vs below median) 4.507 (1.4–14.9) 0.013 0.880 (0.13– 5.7) 0.8 
miR-193a-3p
(above vs below median) 3.257 (1.07–9.85) 0.035 0.721 (0.31– 4.6) 0.7 
miR-193a-5p 
(above vs below median) 2.160 (0.63–7.29) 0.2 / / 
Legend: HR: hazard ratio; CI: confidence interval; M: male; F: female; AC: atypical carcinoid; TC: typical carcinoid.
Oncotarget27539www.oncotarget.com
Figure 2: MiR-100 modulates mTOR expression levels in carcinoid cell lines. (A) mTOR mRNA and miR-100 expression 
levels in H727 and UMC11 cell lines; (B) Luciferase assay showing reporter decreased activity after co-transfection of wild-type mTOR 
3ʹUTR with miR-100 in HEK293 cells (miR-100), as in the positive control (ctrl +; see Materials and Methods for details; NT: untreated 
cells); (C and E) up-modulation of miR-100 by mimic miR-100 significantly reduces mTOR mRNA expression in both H727 and UMC11 
cell lines; (D and F) miR-100 down-regulation by inhibitor miR-100 increases mTOR levels in both H727 and UMC11 cell lines; Western 
blot analysis shows that mimic and inhibitor miR-100 modulate TORC1-associated proteins but not TORC2 complex in H727 (G) and 
UMC11 (H) cells (see Supplementary Figure 2 for Western blot bands quantification). Each experiment was repeated in triplicate. All data 
in the Figure were represented as mean ± SEM. *p < 0.05,**p < 0.01,***p < 0.001.
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decreased proliferation of H727 cells as compared to 
control mimic whereas the inhibition of miR-100 induced 
a significant increase of cell proliferation as compared 
to control inhibitor (Figure 4A and 4B) (p < 0.05). By 
contrast, wound healing assay showed that miR-100 
over-expression led to significant enhancement of the 
migration of H727 cells, whereas knockdown of miR-100 
significantly reduced the percentage of cellular migration 
as compared with inhibitor control (Figure 4C and 4D) 
DISCUSSION
Among the strategies for targeting cellular pathways 
as a therapeutic tool in cancer, miRNAs have shown 
promising therapeutic benefit either by elevating levels 
of tumor suppressor or inhibiting oncogenic miRNAs. 
MicroRNA patterns of expression in neuroendocrine lung 
tumors have been already evaluated in some studies to 
identify novel reliable biomarkers for differential diagnosis 
Figure 3: MiR-100 inhibition sensitizes lung carcinoid cells to rapamycin treatment. miR-100 up-modulation reduced 
cytotoxic effect of rapamycin in UMC11 and H727 cells (A and C, respectively), whereas miR-100 suppression sensitized lung carcinoid 
cell lines  (UMC11 and H727 cells, (B and D), respectively). Moreover, opposite effects on apoptosis were observed in H727 cells 
transfected with mimic miRNA-100 (E) or inhibitor miRNA-100 (F) under rapamycin treatment (see Results for details). Triplicate wells 
for each condition were examined, and each experiment was repeated in triplicate. Data was represented as mean ± SEM. *p < 0.05.
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and prognosis [22–24]. However, the role of miRNAs 
in targeting the mTOR pathway in neuroendocrine lung 
cancer is totally unexplored. The aim of this study was 
therefore to identify miRNAs specifically targeting the 
mTOR pathway in lung neuroendocrine neoplasms as well 
as to validate their potential functional role as modulators 
of mTOR pharmacological inhibition. The overall results 
of the present study are summarized in Figure 5.
The first goal of this study was indeed to understand 
whether miRNAs might be active modulators of mTOR 
pathway in lung carcinoids as compared to high grade 
neuroendocrine carcinomas. Seven miRNAs were selected 
and tested in tissue samples from a large series of lung 
neuroendocrine neoplasms in correlation with mTOR 
gene expression. Five miRNAS (miR-99b, miR-100, 
mi-R155, miR-193a-3p, miR-193a-5p) were inversely 
correlated with mTOR expression, thus suggesting an 
active interference with mTOR transcription, although 
they were not significantly correlated with phosphorylated 
forms of mTOR and p70S6K proteins, possibly as the 
result of the complexity of mechanisms leading to mTOR 
pathway activation status in vivo. Moreover, all five were 
positively correlated each other at a variable extent and 
were heterogeneously distributed within each tumor type 
category, supporting that they might interplay either as 
coexistent or alternative mechanisms in individual tumors 
in regulating mTOR gene expression. Interestingly, the 
high expression of miR-100, miR-193a-3p and miR-
193a-5p was also associated in the group of carcinoids 
with specific clinical and pathological characteristics of 
aggressiveness, thus supporting that – either interfering 
with mTOR pathway or modulating tumor cells in a more 
complex network – they are relevant actors in controlling 
tumor growth and progression in these tumors. 
Expression of miR-100 in human malignancies is 
variable and modulates tissue-specific functions being 
either up-regulated [25–28] or down-regulated [15, 29–33] 
in cancer cells. Indeed, we subsequently aimed at further 
supporting our findings on the biological functions of miR-
100 in lung carcinoid, testing in vitro its role to modulate 
cell proliferation and invasive capacity. Our data overall 
support a positive control of miR-100 in invasive capacity 
of lung carcinoid cells which mirror the association of its 
over expression with higher tumor stage and positive lymph 
node status. By contrast, miR-100 high expression was 
associated with decreased cell proliferation. Even though 
this latter finding might be in contrast with the association 
with tumor grade we observed, it is worth to notice that 
high miR-100 expression was inversely correlated to Ki-67 
proliferation index in our lung carcinoid series, even if not 
Figure 4: MiR-100 modulates proliferation and migration of lung carcinoid cells. WST-1 assay indicated that miR-100 
over-expression reduced cell proliferation (A) but enhanced cell motility (C) in H727 cells. By contrast, miR-100 inhibition increased cell 
proliferation (B) but suppressed cell motility (D). Duplicate wells for each condition were examined, and each experiment was repeated in 
triplicate. Data was represented as mean ± SEM. *p < 0.05,**p < 0.01
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reaching statistical significance (data not shown). In terms 
of survival, high miR-100 was associated to shorter time 
to progression, although statistical significance was lost at 
multivariate survival analysis, possibly due to the limited 
number of events and the different distribution in tumor 
histotypes. Few data, mainly limited to gastrointestinal 
cancers [34, 35], are available about the association of 
miR-193a-3p and miR-193a-5p with tumor characteristics 
and, so far, support – as for miR-100 in the same location 
- an onco-suppressive role of miR-193a family members. 
However, as already discussed above – our data in lung 
carcinoids again suggest that the same miRNA might have 
variable effects according to the tissue where it is expressed. 
The second goal of the present study was to assess 
the potential correlation between miRNA expression and 
sensitivity to mTOR inhibition. First, we validated which 
of the three miRNAs showing the best inverse correlation 
with mTOR at the tissue level (miR-100, miR-193a-3p 
and miR-193a-5p) directly represses mTOR expression 
in lung carcinoid cells, a preliminary step for further 
functional studies. MiR-100 was indeed the unique to be 
both inversely correlated at baseline with mTOR gene 
expression and to reduce mTOR expression at Luciferase 
assay. Transfection of both H727 and UMC11 cells with 
either mimic-miR-100 or inhibitor miR-100 confirmed the 
role of miR-100 in controlling mTOR gene and protein 
expression. A selective impairment of TORC1 complex by 
miR-100 was demonstrated by the specific modulation of 
phosphorylation of mTOR in S2448 and p70S6K in T389. 
More interestingly, forced up- or down-regulation of miR-
100 desensitized or sensitized, respectively, both H727 
and UMC11 cells to rapamycin treatment, thus showing 
that miR-100 modulation is able to influence response to 
mTOR inhibitors, and that mTOR levels are predictive of 
response to these agents. The major pitfall of our in vitro 
data is related to the limited availability of commercial 
lung carcinoid cell lines, with special reference to those 
growing adherent and not in suspension. However, our 
data support the concept that miR-100 may be responsible 
for inter-individual heterogeneity of mTOR expression 
in specific tumor types and even for the occurrence of 
dynamic changes of mTOR expression (and responsiveness 
to mTOR inhibitors) in individual patients. However, also 
in this context literature data are controversial, being over-
expression of miR-100 either responsible of decreased or 
increased sensitivity to mTOR inhibitors, in lymphoblastoid 
[36] or ovarian cancer [15], respectively. The lack of wide 
correlation data between mTOR expression and mTOR 
Figure 5: Schematic diagram illustrating the overall results of the present study. Solid arrows represent conclusions based 
on our results. Dotted arrows illustrate possible correlations or hypotheses not directly supported but suggested by the present findings, or 
to be validated. 
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inhibitor responsiveness make our results speculative, and 
our case series failed to be supportive of this hypothesis 
since no lung carcinoid patient in our cohort was treated 
with mTOR inhibitors at the time of this study. However, 
our data overall contribute to strengthen the potential 
promising benefit of combining miRNA-selective mTOR 
targeting and mTOR inhibitors as potent therapeutic tools 
in advanced lung carcinoids, supporting also that miR-100 
expression testing might be a potential predictive biomarker 
of response to mTOR inhibition strategies. 
In conclusion, in this study we: i) identified a set 
of miRNAs associated with mTOR expression and tumor 
characteristics in lung carcinoids; ii) demonstrated that 
miR-100 actively participates to the regulation of mTOR 
expression in lung carcinoid cells, and that its modulation 
influences responsiveness to mTOR inhibitors thus 
representing a novel target to sensitize lung carcinoid cells 
to this therapeutic strategy.
MATERIALS AND METHODS
Tumor tissue samples
A retrospective cohort of 142 formalin-fixed and 
paraffin embedded (FFPE) samples of surgically resected 
lung neuroendocrine neoplasms with available clinical 
and pathological characteristics, including 50 typical 
carcinoids (TCs), 42 atypical carcinoids (ACs), 29 large 
cell neuroendocrine carcinomas (LCNECs) and 21 
small cell carcinomas (SCLCs), was collected from the 
pathology files of the University of Turin at San Luigi 
Hospital, Orbassano, Turin (Supplementary Table 1). All 
cases were anonymized by a pathology staff member not 
involved in the study and re-classified according to the 2015 
WHO classification of lung tumors [37]. In all cases, the 
neuroendocrine phenotype was confirmed by positivity for 
at least one general neuroendocrine marker (synaptophysin, 
clone SP11, diluted 1:150, ThermoScientific, and/or 
chromogranin A, clone LK2H10, diluted 1:1500, DBS) 
and the proliferation index was assessed by testing Ki-67 
protein expression (clone MIB-1, DakoCytomation). All 
diagnostic immunohistochemistry was performed using an 
automated immunostainer (Omnis, Dako). The proposal 
for lung neuroendocrine neoplasm tumor grading was 
also applied [38]. The Institutional Review board of the 
hospital approved the study (Ethics Committee Approval 
no. 167/2015-prot.17975, October 21, 2015).
Bioinformatics analysis 
The bioinformatics validation of selected miRNAs 
based on the literature and through the screening of 
additional mRNAs specifically targeting mTOR performed 
by using Web-available softwares, including miRBase and 
NCBI mapviewer. The predicted target genes and their 
conserved sites of seed region binding with each miRNAs 
were investigated using the TargetScan (release 5.0; http://
www.targetscan.org/) and PicTAR (https://pictar.mdc-
berlin.de) programs.
RNA isolation, cDNA synthesis and microRNA 
expression analysis 
Total RNA was isolated from tissue specimens, 
using miRNase miRNA isolation FFPE Kit (Qiagen), 
according to manufacturer’s instructions. The purity 
and the quantity of miRNA were assessed using the 
BioPhotometer (Eppendorf). All samples were diluted 
to a final concentration of 40 ng/μl. For quantitative 
Real-Time PCR, cDNA was prepared using the TaqMan 
MicroRNA Reverse Transcription Kit (Life Technologies) 
as previously described [22]. Reverse transcriptase (RT) 
reactions containing 40 ng of total RNA were performed 
in a volume of 15 μl with the following conditions: 
16° C for 30 min, 42° C for 30 min, 85° C for 5 min, 
and 4° C for 5 min. Reactions without addition of reverse 
transcriptase (RT− controls) were performed along with 
cDNA synthesis of each sample and used in subsequent 
procedures to control the potential genomic DNA 
contamination. Commercially available assays for mTOR, 
candidate miRNAs and housekeeping genes (Taqman, Life 
Technologies, Supplementary Table 2) were employed 
following protocols already described [22]. The amount 
of target miRNAs was normalized relative to the amount 
of RNU6B. ΔCt was calculated using the following 
mathematical formula: ΔCt = Ct sample- Ct control.
Immunohistochemistry
In all samples, the expression of phosphorylated forms 
of mTOR (p-mTOR; clone 49F9, Ser2448, diluted 1:100; 
Cell Signalling) and p70S6K (p-p70S6K; clone1A5, Thr389, 
diluted 1:400; Cell Signalling) was assessed by means of 
immunohistochemistry using an automated platform (Ventana 
BenchMark, Roche), and scored by using the H-score (range 
0–300), as previously published by our group [8]. 
Cell lines 
H727 and UMC-11 (lung carcinoid cell lines) and 
HEK-293T (human embryonic kidney cell line 293T 
used for luciferase assay) were from the American Type 
Culture Collection (ATCC). Cell lines were maintained in 
RPMI-1640 (H727 and UMC-11) or DMEM (HEK-293T) 
supplemented with 10% fetal calf serum, 2 nM glutamine, 
penicillin (25 U/ml), and streptomycin (25 µg/ml) 
(all from Sigma-Aldrich) in a humidified atmosphere 
containing 5% CO2 at 37° C. 
Cell transfections 
For functional analysis, hsa-miR-100, hsa-miR-
193a-3p and hsa-miR-193a-3p mimics and inhibitors 
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and non-targeting miRNA mimic and inhibitor controls 
from Thermo-Scientific (Supplementary Table 2) were 
transfected using Lipofectamine RNAiMAX (Invitrogen) 
according to the manufacturer’s instructions. In brief, cells 
were plated in 6 cm diameter cell culture dishes to 60% 
confluence. For each dish, 20 pmol of mimics or inhibitors 
and 6 μl of transfection reagent were added into 1.5 ml of 
antibiotic-free opti-MEM medium (Invitrogen), separately, 
and then mixed together for forming the transfection 
complex. The transfection complex was added to cells 
and incubated for 24 h before replacing with complete 
medium. Overexpression or inhibition of miRNA after 
transfection was maintained for at least 10 days (assessed 
by real-time-PCR, not shown). Co-transfection of the 
mimic/inhibitor and plasmid DNA was conducted using 
Lipofectamine 2000 (Invitrogen). All transfections were 
performed according to the manufacturer’s protocol.
Pharmacological tests
Basal and transfected cell lines were plated into 96-
well plates and treated, in triplicate, with different doses 
of rapamycin (Cell Signaling), from 0.1 nmol/liter to 
500 nmol/liter; for 72 h. Cell proliferation was assessed 
by colorimetric Cell Proliferation Reagent WST-1 (Roche 
Applied Science), following the supplied protocol. The 
absorbance was determined using a microplate reader 
(iMARK microplate reader, Biorad) at a test wavelength 
of 450 nm. The variation in drugs sensitivity was analyzed 
calculating IC50 value. Triplicate wells for each condition 
were examined, and each experiment was repeated in 
triplicate. 
Cell proliferation and wound healing assay
H727 cells transfected with mimic or inhibitor miR-
100 and with controls were plated into 96-well plates 
and after 0, 24, 48, 72, 96 h after transfection, 10 µl of 
WST-1 salt (Roche) were added to each well. Plates were 
incubated for 1 h before measuring the absorbance at 
450nm in a microplate reader (Biorad). For wound healing 
assay transfected cells were plated into 6-well plates. 
After the cells reached sub-confluence, wounds were 
created using a 200-µl pipet tip. The cells were rinsed 
with medium to remove any free-floating cells. Cells 
were cultured at 37° C and wound healing was observed 
at different time points and photographed (magnification, 
×100). Duplicate wells for each condition were examined, 
and each experiment was repeated in triplicate.
Apoptosis assay 
H727 cells with or without miR-100 over-expression 
(see Results section) were exposed to 1 µM and 10 µM 
rapamycin for 48 hours and then collected. Apoptosis 
was measured by staining the cells with Annexin V-FITC 
and PI using PE Annexin V apoptosis detection kit (BD 
pharmingen) and analyzed using using BD FACSCalibur 
flow cytometer. 
Western blot analysis 
Whole protein extracts from normal and transfected 
cells were prepared in RIPA lysis buffer (Sigma) 
supplemented with 1% protease and 1% phosphatase 
inhibitor cocktail (Complete; Roche Diagnostic). For 
each experiment, protein concentration was determined 
using BCA protein assay kit (Pierce), and 50 μg of protein 
were resolved on a 8% SDS-PAGE gel and transferred to 
nitrocellulose membranes. Blots were blocked with 5% 
BSA in Tris-buffered saline-Tween 0.1% and incubated 
overnight at 4° C with mTOR (1:1000; clone L27D4, Cell 
Signalling), phospho-mTOR (1:1000; clone 59.S2448, 
S2448, Santa Cruz), phospho-p70S6K (1:1000; clone 
1A5, T389, Cell Signalling), phospho-AKT (1:1000; 
polyclonal, S473, Santa Cruz), phospho-NDRG1 (1:1000; 
polyclonal, T346, Cell Signalling) and vinculin (1.1000; 
clone 7F9, Santa Cruz). Immuno-reactive proteins were 
visualized using horseradish peroxidase-conjugated 
anti-mouse antibody and enhanced chemi-luminescence 
substrate (Amersham) and images acquired with Chemi-
doc (Biorad). The optical density of the appropriately 
sized bands was measured using the ImageJ free-software 
(http://rsbweb.nih.gov/ij/).
Luciferase assay 
Luciferase reporter construct was PCR-amplified 
from the wild-type 3ʹUTR of human mTOR mRNA 
containing the putative binding sites for miRNAs and 
inserted into the XhoI and NotI sites downstream of the 
stop codon of Renilla luciferase in psiCHECK 2 vector 
(Promega) resulting in the psiCHECK 2_3ʹmTOR 
plasmid. Plasmid sequence was verified by using Sanger 
method (data not shown). HEK-293T cells were grown 
in a 48-well plate were co-transfected with 12.5 nM of 
either NC or miRNAs duplex, 20 ng of psiCHECK-2 or 
psiCHECK-2_3ʹ-mTOR reporter plasmids. Luciferase 
assay was performed according to the manufacturer 
protocol (Promega). The psiCHECK-2 scramble-vector 
and siRNA anti-renilla were used as negative and positive 
control, respectively. Transfection was performed 
in duplicate and was repeated at least three times in 
independent experiments.
Statistical analysis 
Tissue and in vitro data were analyzed using 
appropriate statistical tests (Chi-square, Student’s t, 
ANOVA and Spearman tests). Carcinoid patients only 
were used for survival analyses and follow up data were 
available in 69 cases. Kaplan–Meier survival times were 
calculated, and subgroups were compared by the log-
rank test. Median miRNA expression levels were used as 
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cut-offs. Multivariate Cox regression model was used to 
assess the association of different clinical, pathological 
and molecular variables with time to progression. Due to 
the low number of deaths overall survival analysis was not 
performed. IBM SPSS statistica software version 22 (IBM 
corporation, Armonk, USA) was used and p value of less 
than 0.05 was considered statistically significant. 
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